Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.71 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.61 |
| ▸ | APP | P05067 | 5/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CA6 | P23280 | 2/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647364 | 1.00 | PTGS1 (0.71) | PTGS1NFE2L2APPCA12CA1 | |
| SCHEMBL28837412 | 0.88 | PTGS1 (0.57) | PTGS1NFE2L2APPCA12CA1 | |
| SCHEMBL9678787 | 0.86 | APP (0.74) | PTGS1NFE2L2APPCA12CA1 | |
| Trans-4,4'-Dihydroxystilbene SCHEMBL491346 | 0.86 | APP (0.74) | PTGS1NFE2L2APPCA12CA1 | |
| SCHEMBL13766470 | 0.86 | NFE2L2 (0.78) | PTGS1NFE2L2APPALOX5PTGS2 | |
| Trans-4,4'-Dihydroxystilbene SCHEMBL13339135 | 0.86 | APP (0.74) | PTGS1NFE2L2APPCA12CA1 | |
| SCHEMBL6266989 | 0.86 | APP (0.74) | PTGS1NFE2L2APPCA12CA1 | |
| SCHEMBL700051 | 0.86 | NFE2L2 (0.78) | PTGS1NFE2L2APPALOX5PTGS2 | |
| SCHEMBL22468800 | 0.86 | NFE2L2 (0.78) | PTGS1NFE2L2APPALOX5PTGS2 | |
| Trans-4,4'-Dihydroxystilbene SCHEMBL145659 | 0.86 | APP (0.74) | PTGS1NFE2L2APPCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503686-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-108546277-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-108314697-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-109503686-A | New nucleoside phosphoramidate compound and its application | 南京圣和药业股份有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-108546277-A | New nucleoside phosphoramidate compound and its application | 南京圣和药业股份有限公司 | 2018-09-18 | — | — | CN | disclosed |
| CN-108314697-A | New nucleoside phosphoramidate compound and its application | 南京圣和药业股份有限公司 | 2018-07-24 | — | — | CN | disclosed |
| US-9963480-B2 | Nucleoside phosphoramidate compound and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2018-05-08 | — | — | US | disclosed |
| CN-104031104-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2018-04-10 | — | — | CN | disclosed |
| EP-2940031-B1 | NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS FOR USE IN THE TREATMENT OF HCV | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2017-09-27 | — | — | EP | disclosed |
| US-20170260126-A1 | SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION | UNIV OXFORD INNOVATION LTD (GB) | 2017-09-14 | — | — | US | disclosed |
| US-20150361123-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2015-12-17 | — | — | US | disclosed |
| EP-2940031-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361123-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | PNP, NUDT1, SLC28A1 | PTGS1 4265/4885NFE2L2 4337/4885APP 3873/4885 |
| US-20170260126-A1 | SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION | LDLR, NR1H2, SREBF1 | PTGS1 347/4885NFE2L2 777/4885APP 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.